Ulo Iphase ds8201A

Iphase ds8201A

Nkọwa mkpụmkpụ:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Kpọtụrụ ugbu a Tinye na Cartzụ ahịa

Nkọwa nke ngwaahịa

Mkpado Ngwaahịa

Nke keibesti DS - 8201A, nke a makwaara dị ka Trastuzubib Deruxumecan Derextcan (TRX) Ọ na-agwakọta her2 - na-echekwa monoconal (yiri trastrumumab) na potoisomerase m na-egbochi (Duxxecan) dị ka paykwụ cytotoxic. Ọgwụ ọgwụ na-enye ọgwụ na-eme ọgwụ ozugbo na cell cell na-ekwupụta ya2, na-arụ ọrụ mgbe ị na-eme ka imebi mkpụrụ ndụ nkịtị.

Udi:
Kasiansin
Ihe mba.:
015200.02
Ogo nkeji:
200UL, 2MG / ml
Anụ ahụ:
N / a
Umu:
N / a
Ọnọdụ nchekwa na ụgbọ njem:
Chekwaa na - 70 Celsius C. Akọrọ akọrọ.